OncoMatch/Clinical Trials/NCT06783569
A First-in-Human Escalation and Expansion Study of Patients With Advanced Solid Tumors
Is NCT06783569 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies JR8603 for solid tumors.
Treatment: JR8603 — The goal of this clinical trial is to learn if the investigational drug (JR8603) is safe and effective in treating patients with solid tumors after their initial rounds of treatment with other drugs did not work.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Gastric Cancer
Colorectal Cancer
Biomarker criteria
Allowed: HER2 (ERBB2) positive
HER2-positive gastric or EGJ cancer
Allowed: HER2 (ERBB2) negative
HER2-negative gastric or EGJ cancer
Allowed: MMR deficient
MMR-deficient (dMMR)/microsatellite instability-high (MSI-H)
Allowed: MMR proficient
proficient mismatch repair (pMMR)
Allowed: BRAF wild-type
RAS and BRAF wild-type (WT)
Allowed: KRAS wild-type
RAS and BRAF wild-type (WT)
Allowed: BRAF mutation
BRAF mutation
Allowed: KRAS mutation
RAS mutation
Disease stage
Required: Stage III, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic standard therapy — all
which has progressed on, or patients intolerant to, all standard therapy, or no standard therapy available, or it is documented that the therapy is refused by the patient
Cannot have received: systemic anticancer chemotherapy, targeted agents, antibody therapy for cancer, immunotherapy for cancer, hormonal therapy, or an investigational agent
Received systemic anticancer chemotherapy, targeted agents, antibody therapy for cancer, immunotherapy for cancer, hormonal therapy, or an investigational agent within 2 weeks or 5 half-lives (whichever is shorter) prior to start of study drug treatment
Lab requirements
Blood counts
ANC ≥1.5 × 10^9/L (≥1500/mm3); Platelet count ≥100 × 10^9/L (≥100,000/mm3) (no platelet transfusion within 14 days prior to enrollment)
Kidney function
Estimated creatinine clearance by Cockcroft-Gault or eGFR ≥60 mL/min
Liver function
Total bilirubin ≤1.5 × ULN, unless known Gilbert syndrome (≤3 × ULN); AST and ALT ≤2.5 × ULN or ≤5 × ULN for patients with known liver metastases
Cardiac function
INR, PT, and aPTT ≤1.5 × ULN. If receiving anticoagulant therapy, PT and aPTT must be within therapeutic range of intended use of anticoagulants
Adequate organ and bone marrow function defined by: ANC ≥1.5 × 10^9/L (≥1500/mm3); Platelet count ≥100 × 10^9/L (≥100,000/mm3) (no platelet transfusion within 14 days prior to enrollment); Total bilirubin ≤1.5 × ULN, unless known Gilbert syndrome (≤3 × ULN); AST and ALT ≤2.5 × ULN or ≤5 × ULN for patients with known liver metastases; Estimated creatinine clearance by Cockcroft-Gault or eGFR ≥60 mL/min; INR, PT, and aPTT ≤1.5 × ULN. If a patient is receiving anticoagulant therapy, PT and aPTT must be within therapeutic range of intended use of anticoagulants
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify